AMGEN’S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL AmgenAmgen’s cholesterol shot prevented first heart attacks and strokes, more detailed data affirm statnews.comAmgen cholesterol drug cuts risk of first cardiac event by 25% ReutersEvolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV TCTMD.comPCSK9 inhibitor reduced major CVD events in adults with no prior heart attack or stroke www.heart.org
